Compare OUST & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OUST | IMNM |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2020 | 2020 |
| Metric | OUST | IMNM |
|---|---|---|
| Price | $34.32 | $27.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $39.25 | $32.80 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 48.56 | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $169,384,000.00 | $6,941,000.00 |
| Revenue This Year | $33.20 | N/A |
| Revenue Next Year | $37.27 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 52.46 | N/A |
| 52 Week Low | $16.40 | $8.67 |
| 52 Week High | $63.79 | $30.06 |
| Indicator | OUST | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 53.34 |
| Support Level | $31.95 | $18.72 |
| Resistance Level | $50.62 | $30.06 |
| Average True Range (ATR) | 2.91 | 1.45 |
| MACD | -0.98 | -0.18 |
| Stochastic Oscillator | 2.70 | 39.49 |
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and the Pacific, Europe, the Middle East, and Africa. It derives maximum revenue from the Americas. The Company operates as one reportable and operating segment, which relates to the sale and production of lidar sensor kits.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.